How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration?

Eye (Basingstoke)

Volumn 28, Issue 7, 2014, Pages 832-837

  Rees, A ^a   Zekite, A ^a   Bunce, C ^a   Patel, P J ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; BLINDNESS; CERTIFICATION; ETHNICITY; FEMALE; GEOGRAPHIC ATROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL BLINDNESS; REGISTRATION; RETINA MACULA AGE RELATED DEGENERATION; UNITED KINGDOM; VISUAL IMPAIRMENT;

EID: 84922011650     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.103     Document Type: Article

References (23)

1. Sorsby A. The Causes of Blindness in England 1948-50. HMSO: London, 1953.
2. SorsbyA.Blindness in England 1951-54. HMSO: London, 1956.
3. Sorsby A. The Incidence and Causes of Blindness in England and Wales 1948-62. Reports of Public Health and Medical Subjects Vol 114. HMSO: London, 1966.
4. Sorsby A. The Incidence and Causes of Blindness in England and Wales 1963-8. Reports of Public Health and Medical Subjects Vol 128. HMSO: London, 1972.
5. Department of Health and Social Security. Blindness and Partial Sight in England 1969-76. Reports of Public Health and Medical Subjects Vol 129. HMSO: London, 1979.
6. Government Statistical Service. Causes of Blindness and Partial Sight among Adults in 1976-77 and 1980/81. HMSO: London, 1988.
7. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales April 2007-March 2008. Eye 2010; 24: 1692-1699.
8. Rostron E, McKibbin M. Visual impairment certification secondary to ARMD in Leeds, 2005-2010: Is the incidence falling? Eye (Lond) 2012; 26: 933-936.
9. Government Statistical Service. Population estimates for UK, England and Wales 2007-2008. www.statistics.gov.uk.
10. Lievesley N. The future ageing of the ethnic population of England and Wales. www.cpa.org.uk.
11. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom. Br J Ophthalmol 2003; 87: 312-317. (Pubitemid 36307906)
12. Parliament UKThe aging population. http://www.parlia ment.uk/business/ publications/research/key-issues-forthe-new-parliament/value-for-money-in- public-services/ the-Ageing-population/.
13. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: Year 2000 to 2010. Am J Ophthalmol 153(2): 209-213.
14. Klein R, Li X, Kuo JZ, Klein BE, Cotch MF, Wong TY et al. Associations of candidate genes to age-related macular degeneration among racial/ethnic groups in the multi-ethnic study of atherosclerosis. Am J Ophthalmol 2013; 156(5): 1010-1020.e1.
15. Betancourt JR, Green AR, Carrillo JE, Ananeh-Firempong 2nd O. Defining cultural competence: A practical framework for addressing racial/ethnic disparities in health and health care. Public Health Rep 2003; 118(4): 293-302. (Pubitemid 36828331)
16. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
17. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
18. ABC Trial InvestigatorsTufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): Multicentre randomised double masked study. BMJ 2010; 340: C2459.
19. IVAN Study InvestigatorsChakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. [published erratum appears in Ophthalmology 2012;119(8):1508] Ophthalmology 2012; 119(7): 1399-1411.
20. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012; 119(7): 1388-1398.
21. Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Queré S et al. for the LUMIERE Study Group. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: The Lumiere Study. Retina 2013; 33(3): 474-481.
22. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009; 148(3): 409-413.
23. Leamon S, Simkiss P, Zekite A, Seeberan R, Bunce C. Numbers of people newly certified and registered with sight loss in England 2010-2011. Vision UK Conference 2012.